Home/Pipeline/NBI-1117567

NBI-1117567

Schizophrenia

Phase IActive

Key Facts

Indication

Schizophrenia

Phase

Phase I

Status

Active

Company

Neurocrine Biosciences

About Neurocrine Biosciences

Neurocrine Biosciences has successfully transitioned from a discovery-focused entity to a fully integrated commercial leader in neuroscience. Its mission is to relieve suffering through brave science, exemplified by the blockbuster success of INGREZZA for tardive dyskinesia and a growing portfolio in movement disorders and endocrinology. The company's strategy leverages deep neurobiological expertise to advance a diversified pipeline, pursue strategic collaborations, and expand the labels of its commercial assets to drive sustainable growth.

View full company profile

Therapeutic Areas

Neurological Neuroendocrine Neuropsychiatric

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Olanzapine LAI (TEV-‘749)	Teva	Phase 3	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active
Preclinical Kv3 Modulators	Autifony Therapeutics	Preclinical	Active